Ultime notizie per Addex Therapeutics (NASDAQ:ADXN) Azioni

Addex Therapeutics

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics Ltd

Oppenheimer analyst Rick Schafer maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Outperform and lowers the price target from $330 to $300.

News

Price Target

Analyst Ratings

NXPI

Oppenheimer Maintains Outperform on NXP Semiconductors, Lowers Price Target to $300

FREYR Battery (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FREY#NYSE">FREY</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent.

Earnings

Earnings Misses

FREY

FREYR Battery Q3 2024 GAAP EPS $(0.20) Misses $(0.18) Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy and maintains $35 price target.

Reiteration

STOK

HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target

WIIM

PACS

PACS Group shares are trading lower after the company announced postponement of Q3 results and disclosure on civil investigative demands from the federal government.

Guidance

Freyr Provides 2025 EBITDA Guidance Of $75M - $125M, Expects To Exit 2025 At Full-year Run Rate EBITDA Of $175M - $225M

Freyr Battery Announced An Agreement To Acquire The U.S. Solar Manufacturing Assets Of Trina Solar Co Ltd. For Total Consideration Of $340M

National Vision Holdings Reiterates FY24 Outlook: Sees Revenues Of $1.820B-$1.840B Vs. $1.840B Estimate, With Adjusted EPS Of $0.45 - $0.50 Vs. $0.48 Estimate

Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) sees Q4 sales to be up 5 to 7% year-over-year.

KPLT

Katapult Holdings Sees 5 to 7% year-over-year increase in revenue for Q4.

PACS Group Preliminary Q3 Total Facilities Occupancy 90.5%, Expects To Have Ended Quarter With More Than $600M Of Cash And Available Liquidity

2024 EARNINGS GUIDANCE
LXP now estimates that its net income attributable to common shareholders for the year ended December 31, 2024 will be within an expected range of $0.14 to $0.15 per diluted common share. LXP is tightening its estimated Adjusted Company FFO for the year ended December 31, 2024, to be within an expected range of $0.63 to $0.64 per diluted common share. This guidance is forward looking, excludes the impact of certain items and is based on current expectations.

LXP Industrial Trust Narrows FY24 AFFO Guidance from $0.62-$0.65 to $0.63-$0.64 vs $0.63 Est

PACS Group Reveals Postponement Of Release Of Q3 Results; Says It Received Civil Investigative Demands From Federal Government Regarding Reimbursement And Referral Practices

LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $85.57 million which beat the analyst consensus estimate of $84.98 million by 0.69 percent. This is a 0.17 percent increase over sales of $85.42 million the same period last year.

Earnings Beats

LXP Industrial Trust Q3 AFFO $0.16, Inline, Sales $85.57M Beat $84.98M Estimate

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Buy and maintains $29 price target.

NRIX

Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target

Contracts

Tutor Perini, In A Joint Venture With O&G Industries, Has Been Identified As The Apparent Selected Proposer By The New York City Department Of Design And Construction For The New Manhattan Jail Facility

Needham analyst Quinn Bolton maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and lowers the price target from $96 to $85.

MCHP

Needham Maintains Buy on Microchip Technology, Lowers Price Target to $85

Management

IRBT

iRobot Chief Financial Officer Julie Zeiler To Retire, Effective December 2, 2024; Karian Wong To Succeed Zeiler As Finance Chief

Health Care

General

ENOV

Enovis Expects 2024 Adjusted EPS Of $2.75-$2.80 Versus Prior Expectations Of $2.62-$2.77 And Consensus Of $2.71

National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent. The company reported quarterly sales of $451.515 million which beat the analyst consensus estimate of $451.469 million by 0.01 percent. This is a 2.89 percent increase over sales of $438.820 million the same period last year.

National Vision Holdings Q3 2024 Adj. EPS $0.12 Beats $0.06 Estimate, Sales $451.515M Beat $451.469M Estimate

Enovis Narrowed Its Revenue Range And Adjusted  EBITDA  Expectations For 2024, With Sales Estimated At $2.1B Vs. $2.11B Est. And Adjusted EBITDA Of $373M-$378M Versus Prior Guidance Of $368M-$383M

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Buy and maintains $140 price target.

PCVX

Needham Reiterates Buy on Vaxcyte, Maintains $140 Price Target

Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript

J&J ends work on Addex epilepsy drug candidate ADX71149: report

Addex stock rallies 45% on Indivior collaboration update

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report) and keeping the price target at $...

Positive Outlook for Addex Therapeutics: Significant Collaboration Payments and Promising Pipeline Drive Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Addex Therapeutics (ADXN – Research Report) and Avid...

Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)

Shares of Addex Therapeutics ($ADXN) have rallied in the past few days, soaring by 43%, after the company announced the selection of clinical candi...

Clinical Collaboration Ignites Addex Therapeutics (ADXN) Stock Rally

Addex Therapeutics reports H1 results

Addex Therapeutics GAAP EPS of CHF0.08, revenue of CHF0.12M

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Addex Therapeutics (ADXN – Research Report), with a price...

Buy Rating Affirmed for Addex Therapeutics Amid Promising Clinical Developments and Strategic Neurosterix Spinout

ADXN

INDV

Press Releases

Addex Convenes Annual General Meeting 2024

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Addex's Partner Discontinues ADX71149 development in Epilepsy

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Comments

Addex Therapeutics

Notizie

Ultime notizie per Addex Therapeutics (NASDAQ:ADXN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO